"Изучение нейропротекторных свойств пептидного фрагмента аполипопротеина Е ""COG1410""" тема диссертации и автореферата по ВАК РФ 14.00.25, кандидат медицинских наук Туховская, Елена Александровна

• Туховская, Елена Александровна
• кандидат медицинских наук
• 0

Введение диссертации (часть автореферата) на тему «"Изучение нейропротекторных свойств пептидного фрагмента аполипопротеина Е ""COG1410"""»

Актуальность исследований.8

Цель и задачи исследований.12

Научная новизна работы.12

Основные положения, выносимые на защиту.13

Внедрение результатов' исследования в практику.13

Связь задач исследований с проблемным планом фармацевтических наук.14

Объем и структура диссертации.14

Апробация и публикация результатов исследования.15

ОБЗОР ЛИТЕРАТУРЫ

Заключение диссертации по теме «Фармакология, клиническая фармакология», Туховская, Елена Александровна

Выводы

1. Установлено, что ССЮ1410, при однократном внутривенном введении через 30 минут после экспериментального инсульта у крыс CD, улучшает координацию и уменьшает локомоторную асимметрию.

2. COG 1410 уменьшает объемы инфаркта головного мозга крыс CD после перенесенного инсульта на 10%, по отношению к животным, получавшим растворитель.

3. В исследовании токсических эффектов пептида COGHIO на мышах CD-1, установлено, что основной мишенью токсического действия пептида является сердечно-сосудистая система, а дозы, превышающие терапевтическую в 10, 15 и 20 раз вызывают местную раздражающую реакцию. Также установлены половые различия в реакции на дозу COG1410, превышающую терапевтическую в 20 раз.

4. В радиотелеметрическом исследовании гемодинамических показателей выявлен токсический эффект COG1410 на сердечно-сосудистую систему мышей CD-I. В дозе, на порядок превышающей терапевтическую, пептид COG1410 вызывает острое снижение АД и некомпенсированное падение ЧСС, что позволяет прогнозировать его побочные эффекты при передозировке.

Список литературы диссертационного исследования кандидат медицинских наук Туховская, Елена Александровна, 0 год

1. Виберс, Д.О. Инсульт. Клиническое руководство / Виберс Д.О.,

2. B.Л.Фейгин, Р.Д.Браун /СПБ Диалект бином, 2005. 607 с.

3. Воронина, Т.А. Мексидол, основные эффекты, механизм действия, применение Электронный ресурс. Электрон, дан. (1 файл). - М., 2005. -Режим доступа: http://www.voed.ru/mexidol.htm - Загл. с экрана.

4. Гусев, Е.И. Ишемия головного мозга /Гусев Е.И., Скворцова В.И. / Москва, 2001. 328 с.

5. Гуськова Т.А. Токсикология лекарственных средств /Гуськова Т.А. // Москва. -2003. 153 с.

6. Доклинический прогноз безопасности пирацетама и пикамилона на основе показателей острой токсичности / Бугаева JI. И. и др. // Экспериментальная и клиническая фармакология. 2004. - Том 67, №3.1. C. 61-65.

7. Захаров, В.В. Лечение острой и хронической церебральной ишемии / В.В.Захаров, Н.НЛхно // Фарматека. 2004. - №14. - С.88-92.

8. Кадыков, А.С. Сосудистые заболевания головного мозга. Справочник / А.С Кадыков, Н.В. Шахпаронова / Москва: Миклош, 2006. 191с.

9. Мониторинг неврологического дефицита и нарушений нервной деятельности у крыс с фокальной ишемией головного мозга / Чехонин В.П.и др. // Бюллетень экспериментальной биологии и медицины. 2003. - Т. 135, №6 - С.629-633.

10. Приказ Минздрава РФ № 267 от 19.06.2003 "Об утверждении правил лабораторной практики". Приказ зарегистрирован в Минюсте РФ 25.06.2003 под № 4809. - 18с.

11. Феномен кетамининдуцрованной вращательной асимметрии в оценке двигательных нарушении у крыс с окклюзиеи средней мозговой артерии / С.В.Лебедев и др. // Бюллетень экспериментальной биологии и медицины. 2003. - Т. 135, №5 - С. 500-504.

12. A comparison of long-term functional outcome after 2 middle cerebral artery occlusion models in rats / Roof Robin L. et al. // Stroke. 2001. - Vol. 32. - P. 2648-2657.

13. A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage / J. Gao. et al. // Neurocrit. Care. -2006.-Vol. 4(1).-P. 25-31.

14. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury / Lynch John R. et al. // Experimental Neurology. 2005. - Vol. 192 (1). - P. 109- 116.

15. A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve / Boyles J.K. et al. // J. Clin. Invest. 1989. - Vol. 83(3). - P. 1015-1031.

16. A semiautomated method for measuring brain infarct volume / Swanson R.A. et al. // J. Cereb. Blood. Flow Metab. 1990. - Vol. 10. -P. 290-293.

17. A specific 37,000-Dalton protein that accumulates in regenerating but not in nonregenerating mammalian nerves / Muller H.W. et al. // Science. 1985. -Vol. 228(4698). - P. 499-501.

18. A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity / Marques M.A. et al. // NeuroReport. 1996. - Vol. 7. - P. 2529-2532.

19. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro / Wisniewski T. et al. //Am. J. Pathol. 1994. - Vol. 145. - P. 1030-1035.

20. Allan, S. M. Inflammation in the central nervous system. / Allan, S. M. Rothwell, N. J. // Phil. Trans. R. Soc. Lond. B. 2003. - Vol. 358. - P. 16691677.

21. Altered immune responses in apolipoprotein E-deficient mice / Laskowitz D.T. et al. // J. Lipid Res. 2000. - Vol. 41. - P. 613-620

22. Amyloid-associated proteins a-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer P-protein into filaments / Ma J. et al. // Nature. 1994. -Vol. 372.-P. 92-94.

23. Androgens protect against apolipoprotein E4-induced cognitive deficits / Raber J. et al. // J. Neurosci. 2002. - Vol. 22(12). - P. 5204-5209.

24. Antioxidant mechanisms in apolipoprotein E deficient mice prior to and following closed head injury / Lomnitski L. et al. // Biochim. Biophys. Acta. -1999.-Vol. 1453.-P. 359-368.

25. APOE 4 is associated with obstructive sleep apnea/hypopnea / Gottlieb D. J. et al. // Neurology. 2004. - Vol. 63. - P. 664-668.

26. APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress / Colton C.A. et al. // Neurobiol. Aging. -2002.-Vol. 23.-P. 777-785.

27. АРОЕ and the risk of PD with or without dementia in a population-based study / Harhangi B.S. et al. // Neurology. 2000. - Vol. 54. - P. 1272-1276.

28. ApoE deficiency compromises the blood brain barrier especially after injury / Methia N. et al. // Mol. Med. 2001. - Vol. 7. - P. 810-815.

29. ApoE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response / Lynch J.R. et al. // J. Biol. Chem. -2003. Vol. 278. - P. 48529-48533.

30. ApoE genotype and survival from intracerebral haemorrhage / Alberts, M. J. et al. // Lancet. 1995. - Vol. 346 - P. 575.

31. ApoE genotype influences acquisition and recall following traumatic brain injury / Crawford F.C. et al. // Neurology. 2002. - Vol. 58. - P. 1115-1118.

32. APOE genotype is a major predictor of long-term progression of disability in MS / Chapman J. et al. // Neurology. 2001. -Vol. 56. - P. 312-316.

33. ApoE genotype is a risk factor for neuropathy severity in diabetic patients / Bedlack R. S. et al. // Neurology. 2003. - Vol. 60. - P. 1022-1024.

34. ApoE isoform affects LTP in human targeted replacement mice. / Trommer B. L. et al. // NeuroReport. 2004. - Vol. 15. - P. 2655-2658.

35. ApoE synthesis in human neuroblastoma cells / Dupont-Wallois L. et al. // Neurobiol Dis. 1997. - Vol. 4. - P. 356 -364.

36. Apolipoprotein (apo) E4 enhances amyloid p. peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target / Ye S. et al. // Proc. Natl. Acad. Sci. USA. 2005.-Vol. 102,№51.-P. 18700-18705.

37. Apolipoprotein E 4 is associated with rapid progression of multiple sclerosis / Fazekas F. et al. // Neurology. 2001. - Vol. 57. - P. 853-857.

38. Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid 6-peptide deposition in homozygous APPV717F transgenic / Irizarry M.C. et al. // Acta Neuropathol. 2000. - Vol. 100. - P. 451^*58.

39. Apolipoprotein E affects the CNS response to injury and the development of cerebral edema / Lynch J.R. et al. // Ann. Neurol. 2002. - Vol. 51. - P. 113117.

40. Apolipoprotein E and cognitive performance / Raber J. et al. // Nature. -2000. Vol. 404(6776). - P. 352-354.

41. Apolipoprotein E and mimetic peptide initiate a calcium-dependent signaling response in macrophages / Misra Uma K. et al. // Journal of Leukocyte Biology. 2001. - Vol. 70. - P. 677-683

42. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system / Boyles J.K. et al. // J. Clinlnvest. 1985. - Vol. 76, № 4. - P. 1501-1513.

43. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than ароЕЗ / Sanan D.A. et al. // J. Clin. Invest. 1994. - Vol. 94. - P. 860-869.

44. Apolipoprotein E controls the risk and age at onset of Parkinson disease / Li Y.J. et al.. // Neurology. 2004. - Vol. 62. - P. 2005-2009.

45. Apolipoprotein E epsilon 4 and the risk of dementia with stroke. A population-based investigation / Slooter A.J. et al. // J. Am. Med. Assoc. 1997. - Vol. 277, №10. -P. 818-821.

46. Apolipoprotein E epsilon4 and the risk of unfavorible outcome after aneurismal subarachnoid hemorrhage / Tang J. et al. // Surg. Neurol. 2003. -Vol. 60, №5.-P. 391-396.

47. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing / Jordan B.D. et al. // J. Am. Med. Assoc. 1997. - Vol. 278. - P. 136140.

48. Apolipoprotein E expression by neurons surviving excitotoxic stress / Boschert U. et al. // Neurobiol. Dis. -1999. Vol. 6. - P. 508 -514.

49. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons / Huang Y. et al. // Proc. Natl. Acad. Sci. USA. 2001. - Vol. 98. - P 8838-8843.

50. Apolipoprotein E genotipe and outcome in aneurismal subarachnoid hemorrhage / Leung C.H. et al.. // Stroke. 2002. - Vol. 33. - P. 548-552.

51. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease / Namba Y. et al.'// Brain Res. 1991. -Vol. 541(1). -P. 163-166.

52. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions / Rebeck G.W. et al.. // Neuron. 1993. - Vol. 11. -P. 575-580

53. Apolipoprotein E inhibits neointimal hyperplasia after arterial injury in mice / B. Zhu et al. //Am. J. Pathol. 2000. - Vol. 157. - P. 1839-1848.

54. Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease / Bales K.R. et al. // Proc. Natl. Acad. Sci. USA. 1999. - Vol. 96, № 26. - P. 15233-15238.

55. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: A light and electron microscopic study / Han S.H. et al. // J. Neuropathol. Exp. Neurol. 1994. - Vol. 53(5). - P. 535-544.

56. Apolipoprotein E isoform mediated regulation of nitric oxide release / Brown CM. et al. // Free Radic Biol Med. 2002. - Vol. 32, № 11. - P. 1071-1075.

57. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease / Holtzman D.M. et al. // Proc. Natl. Acad. Sci. 2000. -Vol. 97(6). - P. 2892-2897.

58. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice / Sheng H. et al.. // J. Cereb. Blood. Flow Metab. 1998. -Vol. 18.-P. 361-366.

59. Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection / De Bont N. et al. // J. Lipid Res. 1999. -Vol. 40. - P. 680-685.

60. Apolipoprotein E modulates Alzheimer's Abeta(l-42)-induced oxidative damage to synaptosomes in an allele-specific manner. / Lauderback C.M. et al. // Brain Res. 2002. - Vol. 924. - P. 90-97.

61. Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response / Lynch J.R. et al. // J. Neuroimmunol. -2001.-Vol. 114.-P. 107-113.

62. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets / Elshourbagy N.A. et al. // Proc. Natl. Acad. Sci. 1985. - Vol. 82(1). - P. 203207.

63. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality / Van Oosten M. et al. // J. Biol. Chem. 2001. - Vol. 276. - P. 88208824.

64. Apolipoprotein E protects against NMDA excitotoxicity / Aono M. et al.. // Neurobiol. Dis. 2002. - Vol. 11. - P. - 214-220.

65. Apolipoprotein E protects against oxidative stress in mixed neuronal-glial cell cultures by reducing glutamate toxicity / Lee Yoonki. et al. // Pearlstein Neurochemistry International. 2004. - Vol. 44. - P. 107-118.

66. Apolipoprotein E suppresses glial cell secretion of TNF alpha / Laskowitz D.T. et al. // J. Neuroimmunol. 1997. - Vol. 76. - P. 70-74.

67. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease / Small G. W. et al. // J. Am. Med. Assoc. -1995. Vol. 273. - P. 942-947.

68. Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease / Beffert U. et al. //Ann. N.Y. Acad. Sci. 1996. -Vol. 777. - P. 166174.

69. Apolipoprotein E. Diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease / Huang Y. et al. // J. Mol. Neurosci. 2004. - Vol. 23(3). - P. 189- 204.

70. Apolipoprotein E: High-avidity binding to В -amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease / Strittmatter W.J. et al. // Proc. Natl. Acad. Sci. USA. 1993. -Vol. 90, № 5. - P. 1977-1981.

71. Apolipoprotein E4 forms a molten globule a potential basis for its association with disease / Morrow J.A. et al. //J. Biol. Chem. 2002. - Vol. 277. - P. 50380-50385.

72. Apolipoprotein E4 is probably responsible for the chromosome 19 linkage peak for Parkinson's disease / Martinez M. et al.. //Am. J. Med. Genet. 2005. -Vol. 136B.-P. 72-74.

73. Apolipoprotein E4 potentiates amyloid betta peptide-induced lysosomal leakage and apoptosis in neuronal cells / Ji Z.-S. et al. // J. Biol. Chem. 2002. -Vol. 277. -P. 21821-21828.

74. Apolipoprotein E4: A causative factor and herapeutic target in neuropathology, ncluding Alzheimer's disease / Mahley Robert W.et al.-// NAS. 2006. - Vol. 103.-P.15

75. Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia / Laskowitz D.T. // J.Neuroimmunol. 1997. -Vol. 1-2. - P. 70-74.

76. Apolipoprotein E-derived peptides reduce CNS inflammation: implications for therapy of neurological disease / Laskowitz D.T. et al. // Acta Neurol. Scand. -2006. Vol. 114(Suppl. 185). - P. 15-20.

77. Apolipoprotein E-epsilon 2 and Alzheimer's disease: Genotype influences pathologic phenotype / Lippa C.F. et al. // Neurology. 1997. - Vol. 48(2). -P. 515-519.

78. Apolipoprotein E-epsilon 4 genotype predicts a poor outcome in survivors of traumatic brain injury / Friedman G. et al. // Neurology. 1999. - Vol. 52. -P. 244-248.

79. Apoprotein E suppresses phytohemagglutinin-activated phospholipid turnover in peripheral blood mononuclear cells / E. M. Avila et al. // J. Biol. Chem. -1982. Vol. 257. - P. 5900-5909.

80. Apoproteins in human cerebrospinal fluid / Roheim P.S. et al. // Proc. Natl. Acad. Sci. USA. 1979. - Vol. 76. - P. 4646-4649.

81. Association of apoE polymorphisms with disease severity in MS is limited to women / Kantarci O.H. et al. // Neurology. 2004. - Vol. 62(5). - P. 811-814.

82. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease / Saunders A.M. et al. // Neurology. 1993. -Vol. 43(8).-P. 1467-1472.

83. Association of apolipoprotein E polimorfismwith outcome after aneurismal subarachnoid hemorrhage: a preliminary study / Niskakangas T. et al.. // Stroke.-2001.-Vol. 32.-P. 1181-1184.

84. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis // Schmidt S. et al. // Am. J. Hum. Genet. 2002. - Vol. 70, № 3. - P. 708-717.

85. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins / Pitas R.E. et al. // Biochim. Biophys. Acta. 1987. -Vol. 917(1).-P. 148-161.

86. Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning / Poirier J. et al. // Brain Res. Mol. Brain. Res. -1991.-Vol. 11(2).-P. 97-106.

87. Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease / Harris F.M. et al. // J. Biol. Chem. -2004. Vol. 279(5). - P. 3862-3868.

88. Barger, S.W. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E / Barger S.W., Harmon A.D. // Nature. -1997.-Vol. 388.-P. 878-81.

89. Behavioral changes after focal cerebral ischemia by left middle cerebral artery occlusion in rats / Yamamoto M. et al. // Brain Res. 1988. - Vol. 452. - P. 323-328.

90. Behavioral phenotyping of GFAP-ароЕЗ and -apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology / Hartman R.E. et al. // Exp. Neurol. 2001. -Vol. 170.-P. 326-344.

91. Behavioral recovery patterns in rats receiving the NMDA receptor antagonist MDL 100.453 immediately post-stroke / Markgraf C. et al. // Pharm. Biochem. Behav. 1997. - Vol. 56. - P. 391-397.

92. Binding of human apolipoprotein E to synthetic amyloid В peptide: isoform-specific effects and implications for late-onset of Alzheimer disease /

93. Strittmatter W. J. et al. // Proc. Natl. Acad. Sci. USA. 1993. - Vol. 90. - P. 8098-8102.

94. Bock, H. H. Reelin activates SRC family tyrosine kinases in neurons / H. H. Bock, J. Herz. // Curr. Biol. 2003. - Vol. 13. - P. 18-26.

95. Bonita, R. Epidemiology of stroke / Bonita R. // Lancet. 1992. - Vol. 339. -P. 342 - 344.

96. Bonita, R. Stroke prevention: a global perspective / Bonita R. // Stroke prevention. New York, Oxford Univer. Press, 2001. - P. 259-274.

97. Busse, R. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells / Busse R., Mulsch A. // FEBS Lett. 1990. - Vol. 275. - P. 87-90.

98. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice / Harris F.M. et al.. // Proc.Natl. Acad. Sci. 2003. - Vol. 100. - P. 10966-10971.

99. Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction / Heger J. et al. // Circ. Res. 2002. - Vol. 90.-P. 93-99.

100. Cardiovascular and respiratory effects of endothelin in the ventrolateral medulla of the normotensive rat / Mosqueda-Garcia R. et al. // Hypertension. -1995.-Vol. 26(2). -P. 263-71.

101. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease / Small G. W. et al. // Proc. Natl. Acad. Sci. USA. 2000.- Vol. 97. P. 6037-6042.

102. Chamelian, L. Six-month recovery from mild to moderate traumatic brain injury: the role of APOE-4 allele / Chamelian L., Reis M., Feinstein A. // Brain.- 2004. Vol. 127. - P. 2621-2628.

103. Characterization of 125I.-PD164333, an ETA selective non-peptide radiolabeled antagonist, in normal and diseased human tissues/ Davenport A.P. [et al.] // Br.J.Pharmacol. 1998. - Vol. 123. - P. 223-230.

104. Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats / Poirier J. et al. // Neuroscience. 1993. - Vol. 55, №1.-P. 81-90.

105. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death / Harris H.W. et al. // J. Clin. Invest. 1993. -Vol. 91.-P. 1028-1034.

106. Chylomicrons enhance endotoxin excretion in bile / Read Т. E. et al. //Infect. Immun. 1993. -Vol. 61. -P. 3496-3502.

107. Clinical Trials in head injury / Narayan R.K. et al. // J. of Neurotrauma. -2002.-Vol. 19.-P. 503-557.

108. Closed head injury — an inflammatory disease? / Schmidt O.I. et al. // Brain. Research. Rev. 2005. - Vol. 48. - P. 388-399.

109. CNS synaptogenesis promoted by glia-derived cholesterol / Mauch D.H. et al. // Science. 2001. - Vol. 294. - P. 1354-1357.

110. Cognitive and behavioral assessment in experimental stroke research: Will it prove useful? / DeVries A.C. et al. // Neurosci. Biobehav. Rev. 2001. - Vol. 25.-P. 325-342.

111. Cognitive deficits after focal cerebral ischemia in mice / Hattori K. et al. // Stroke.-2000.-Vol. 31.-P. 1939-1944.

112. Correlation between motor impairment and infarct volume after permanent and transient middle cerebral artery occlusion in the rat / Rogers D.C. et al.. // Stroke. 1997. - Vol. 28. - P. 2060-2066.

113. Crossgrove, J.S. The choroid plexus removes J3 amyloid from brain cerebrospinal fluid / Crossgrove J.S., Li G.J., Zheng W. // Exp. Biol. Med. -2005. Vol. 230. - P. 771-776.

114. Croy, J.E. Two apolipoprotein E mimetic peptides, ApoE(l30-149) and ApoE(141-155)2, bind to LRP1 / Croy J.E., Brandon Т., Komives E.A. // Biochemistry. 2004. - Vol. 43. - P. 7328-7335.

115. Curtiss, L. K. Immunoregulatory plasma low density lipoprotein: the biologic activity and receptor-binding specificity is independent of neutral lipids / Curtiss L. K., Edgington T. S. // J. Immunol. 1981. - Vol. 126. - P. 1382-1386.

116. Czapiga, M. Microglial function in human APOE3 and APOE4 transgenic mice: altered arginine transport / Czapiga M., Colton C.A. // J. Neuroimmunol. -2003. Vol. 134, № 1-2. - P. 44-51.

117. Defective neuronal sprouting by human apolipoprotein E4 is a gain-ofnegative function / Teter B. et al. // J. Neurosci. Res. 2002. - Vol. 68, № 3. - P. 331336.

118. Dekroon, R.M. Synthesis and processing of apolipoprotein E in human brain cultures / Dekroon RM, Armati PJ // Glia. 2001. - Vol. 33. - P. 298 -305.

119. Delayed treatment of ischemia/reperfusion brain injury extended therapeutic window with the proteosome inhibitor MLN519 / Williams Anthony J. et al. // Stroke. 2004. - Vol. 35. - P. 1186-1191.

120. Delayed treatment with an adenosine kinase inhibitor GP683 attenuates infarct size in rats with temporary middle cerebral artery occlusion / Tatlisumak T. et al. // Stroke. 1998. - Vol. 29. - P. 1952-1959.

121. Dietschy, J. M. Turley Cholesterol metabolism in the central nervous system during early development and in the mature animal / Dietschy John M., Stephen D. Turley//J. of Lipid Research. -2004. Vol. 45. - P. 1351-1397.

122. Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain / Morrow J.A. et al. // Biochemistry. -2000.-Vol. 39, № 38.-P. 11657-11666.

123. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro / Nathan B.P. et al. // Science. 1994. - Vol. 264, № 5160. - P. 850-852.

124. Differential effects of natriuretic peptides and NO on LV function in heart failure and normal dogs / Hart C.Y. et al. // Am. J. Physiol. Heart Circ. Physiol. 2001. - Vol. 281. - P. H146-H154.

125. Differential regulation of astrocytic mRNAs in the rat striatum after lesions of the cortex or substantia nigra / Schauwecker P.E. et al. // Exp. Neurol. 1998. -Vol. 149, №1.-P. 87-96.

126. Diffuse Optical Tomography of Cerebral Blood Flow, Oxygenation, and Metabolism in Rat During Focal Ischemia / Culver Joseph P. et al., // J. of Cerebral Blood Flow & Metabolism. 2003. -Vol. 23. - P. 911-924.

127. Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation / T. Hiesberger. et al. // Neuron. 1999. - Vol. 24. - P. 481-489.

128. Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and E receptor 2 / M. Trommsdorff et al. // Cell. 1999. - Vol. 97.-P. 689-701.

129. Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease / Buttini M. et al. // Neuroscience. 2000. - Vol. 97(2).-P. 207-210.

130. Dong, L-M. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low densitylipoproteins / Dong L-M, Weisgraber K.H. // J. Biol. Chem. 1996. - Vol. 271., №32.-P. 19053-19057.

131. Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides / Laskowitz D.T. et al. // Exp .Neurol. 2001. - Vol. 167. - P. 74-85.

132. Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue / Shih S.J. et al. // J. Biol. Chem. 2000. -Vol. 275, № 41. - P. 31567-31572.

133. E. Reversible middle cerebral artery occlusion without craniectomy in rats / Zea Longa E.et al. // Stroke. 1989. - Vol. 20. - P. 84-91.

134. Effect of overexpression of very low density lipoprotein receptor on cell growth / Yoko Wada et al. // Heart and Vessels. 2000. - Vol. 15. - P. 74-80.

135. Effects of a new thyrotropin-releasing hormone derivative on behavioral changes after focal cerebral ischemia in rats / Yamamoto M. et al. // Stroke. -1989. Vol. 20. - P. 362-366.

136. Effects of apolipoprotein E, very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro / Handelmann G.E. et al. // J. Lipid. Res. 1992. - Vol. 33, № 11. - P. 16771688.

137. Endogenous apolipoprotein E suppresses LPS-stimulated microglial nitric oxide production / Laskowitz D.T. et al.. // Neuroreport. 1998. - Vol. 9. - P. 615-618.

138. Evidence for a second alpha 2-macroglobulin receptor / Misra U.K. et al. // J. Biol. Chem. 1994. - Vol. 269. -P. 18303-18306.

139. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy / Hibbs J.D. et al.. // J.Clin.Invest. -1992.-Vol. 89. -P. 867-877.

140. Experimental studies of ischemic brain edema. 1. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area / Koizumi J. et al. // Jpn. J. Stroke. 1986. - Vol. 8. - P. 1-8

141. Expression of apolipoprotein E by cultured vascular smooth muscle cells is controlled by growth state / Majack R.A. et al. // J. Cell. Biol. 1988. - Vol. 107.-P. 1207-1213.

142. Expression of apolipoprotein E during nerve degeneration and regeneration / Ignatius M.J. et al. // Proc. Natl. Acad. Sci. USA. 1986. - Vol. 83, № 4. - P. 1125-1129.

143. Expression of apolipoprotein E in normal and diverse neurodegenerative disease brain / Bao F. et al. // NeuroReport. 1996. - Vol. 7. - P. 1733-1739.

144. Expression of human apolipoprotein E3 or E4 in the brains of apoE-/- mice: Isoform-specific effects on neurodegeneration // Buttini M. et al. // J. Neurosci. 1999. -Vol. 19, № 12. - P. 4867-4880.

145. Expression of the very low-density lipoprotein receptor (VLDL-r), an apoprotein-E receptor, in the central nervous system and in Alzheimer's disease / Christie, R.H. et al. // J. Neuropathol. Exp. Neurol. 1996. - Vol. 55. - P. 491498.

146. Expression of the VLDL receptor in endotelial cells / Wyne K.L. et al. // Arterioscler. Thromb. Vase. Biol. 1996. - Vol. 16. - P. 407-415.

147. Factors governing helical preference of peptides containing multiple alpha,alpha-dialkyl amino acids. / Marshall G.R. et al. // Proc. Natl. Acad. Sci. USA.- 1990.-Vol. 87.-P. 487-91.

148. FHJT influences vasospasm and cognition on noncomatose patients with subarachnoid hemorrhage / Lanterna L.A. et al.. // Neurology. 2005. - Vol. 64.-P. 1238-1244

149. Filament size influences temperature changes and brain damage following middle cerebral artery occlusion in rats / Hajnalka Abraham, et al. // Exp. Brain. Res. -2002. Vol. 142. - P. 131-138.

150. Focal cerebral ischaemia in the rat: Description of technique and early neuropathological consequences following middle cerebral artery occlusion / Tamura A. et al. // J. Cereb. Blood Flow Metab. 1981. - Vol. 1. - P. 53-60.

151. Functional assessments in mice and rats after focal stroke I Hunter A.J. et al. //Neuropharmacology. 2000. - Vol. 39. - P. 806-816.

152. Functional brain abnormalities in young adults at genetic risk for late-onset al.Jzheimer's dementia / Reiman E.M. [et al. // Proc. Natl. Acad. Sci. USA. -2004. Vol. 101. -P. 284-289.

153. Functions of lipoprotein receptors in neurons / Beffert U. et al. // J. of Lipid Research. 2004. - Vol. 45. - P. 403-409.

154. Fyn tyrosine kinase is a critical regulator of Disabled-1 during brain development / L.Arnaud et al. // Curr. Biol. 2003. - Vol. 13. - P. 9-17.

155. Garcia, J.H. Experimental ischemic stroke: a review / Garcia J.H. // Stroke. -1984.-Vol. 15.-P. 5-14.

156. Gender-linked brain injury in experimental stroke / Alkayed N.J. et al.. // Stroke. 1998. - Vol. 29. - P. 159-166.

157. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families / Corder E.H. et al.. // Science. 1993. - Vol. 261, № 5123.-P. 921-923.

158. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells / Piedrahita J.A. et al. // Proc. Natl. Acad. Sci. USA. 1992. - Vol. 89. -P. 4471-4475.

159. Genetic modulation of tau phosphorylation in the mouse / J. Brich. et al. // J. Neurosci. 2003. - Vol. 23. -P. 187-192.

160. Genetics of the apolipoprotein E system in man / Utermann G. et al. // Am. J. Hum. Genet. 1980. - Vol. 32, № 3. - P. 339-347.

161. GFAP-apoE transgenic mice: astrocyte specific expression and differing biological effects of astrocyte-secreted ароЕЗ and apoE4 lipoproteins / Sun Y. et al.. // J. Neurosci. Vol. 18. - P. 3261-3272.

162. Ginsberg, M.D. Combating hyperthermia in acute stroke: a significant clinical concern / Ginsberg M.D., Busto R. // Stroke. 1998. - Vol. 29. - P. 529-534.

163. Ginsberg, M.D. Small animal models of global and focal cerebral ischemia / Ginsberg M.D., Busto R. // Cerebrovascular Disease Pathophysiology, Diagnosis and Management. Maiden, Mass: Blackwell Scientific Publications, 1998.-P. 14-35.

164. Giora, Z. Animal models of stroke / Giora Z., Feuerstein and Xinkang W. // Molecular Medicine Today. 2000. - Vol. 6 - P. 133-135.

165. Glial gene expression during aging in rat striatum and in long-term responses to 6-OHDA lesions / Pasinetti G.M. et al. // Synapse. 1999. -Vol. 31, № 4. -P. 278-284.

166. Glial-neuronal interactions in Alzheimer's disease: the potential role of a "cytokine cycle" in disease progression / Griffin W. S. T. et al.. // Brain Pathol. 1998.-Vol. 8.-P. 65-72.

167. Grabowski, M. Paw-reaching, sensorimotor, and rotational behavior after brain infarction in rats / Grabowski M., Brundin P., Johansson B. // Stroke. 1993. -Vol. 24. - P. 889-895.

168. Grehan, S. Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain / Grehan S., Tse E., Taylor J.M: // J. Neurosci. 2001. - Vol. 21, № 3. - P. 812-822.

169. Guo, L. A dual role for apolipoprotein E in neuroinflammation: anti- and proinflammatory activity / Guo L., LaDu M.J., Van Eldik L.J. // J. Mol. Neurosci. -2004. Vol. 23, № 3. - P. 205-212.

170. Harris, H. W. Chylomicrons alter the hepatic distribution and cellular response to endotoxin in rats / Harris H. W., Rockey D. C., Chau P. // Hepatology.1998.- Vol. 27.-P. 1341-1348.

171. Heart Disease and Stroke Statistics—2006 Update A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee / Thomas Thorn, et al. // Circulation. 2006. - Vol. 113. - P. 85-151.

172. Hemodynamic changes in apolipoprotein E-knockout mice / Hartley Craig J. et al. // Am. J. Physiol. Heart Circ. Physiol. 2000. - Vol. 279. - P. H2326-H2334.

173. Henkey, G. Treatment and secondary prevention of stroke: Evidence, costs, and effects on individuals and populations / Henkey G., Warlow C. // Lancet.1999. Vol. 354. - P. 1457-1463.

174. Hoit, D. Two Faces of Nitric Oxide Lessons Learned From the NOS2 Knockout Brian / Hoit D. // Circ. Res. 2001. - Vol. 89. - P. 289-291.

175. Hossmann, K.A. Experimental models for the investigation of brain ischemia / Hossmann K.A. // Cardiovasc. Res. 1998. - Vol. 39. - P. 106-120.

176. Hossmann, K-A. Animal models of cerebral ischemia. I. Review of literature / Hossmann K-A. // Cerebrovasc. Dis. -1991. Vol. 1. - P. 2-15.

177. Hu, J. Apolipoprotein E attenuates beta-amyloid-induced astrocyte activation / Hu J., LaDu M.J., Van Eldik L.J. // J. Neurochem. 1998. - Vol. 71. - P. 16261634.

178. Huang, Y. Apolipoprotein E and Alzheimer disease / Huang Y. // Neurology. -2006. Vol. 66(Suppl 1). - P. S79-S85.

179. Huang,Y. Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies / HuangYadong // Current Opinion in Drug Discovery & Development. 2006. - Vol. 9, № 5. - P. 627641.

180. Hui, D. Y. Immunoregulatory plasma lipoproteins: role of apoprotein E and apoprotein В / Hui, D. Y., Harmony, T. L., Innerarity, R. W. // J. Biol. Chem. -1980.-Vol. 255.-P. 11775-11781.

181. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain / Kim D.-H. et al. // J. Biol. Chem. 1996. - Vol. 271. - P. 8373- 8380.

182. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms / Dong L.M. et al. // J. Biol. Chem. -1994. Vol. 269, № 35. - P. 22358-22365.

183. Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice / Xu P-T. et al. // Neurobiol. Dis. -1996.-Vol.3.-P. 229-245.

184. Human neural stem cell transplantation reduces spontaneous recurrent seizures following pilocarpine-induced status epilepticus in adult rats / Chua Kon. et al. // Brain Research. 2004. - Vol. 1023. - P. 213- 221.

185. Impairment of the blood-nerve and blood- brain barriers in apolipoprotein E knockout mice / Fullerton S.M. et al. // Exp. Neurol. 2001. - Vol. 169. - P. 13-22.

186. Inapparent hemodynamic exacerbates ischemic damage in a rat microembolic stroke model / Omae T. et al.. // Stroke. 2000. - Vol. 32. - P. 2494-2499.

187. Increased aortic stiffness by pulse wave velocity in apolipoprotein E-deficient mice / Wang Y.X. et al. // Am. J. Physiol. Heart. Circ. Physiol. 2000. - Vol. 278. -P. H428-H434.

188. Increased expression of neuronal apolipoprotein E in human brain with cerebral infarction / Aoki K. et al. // Stroke. 2003. - Vol. 34. - P. 875- 880.

189. Increased neuronal damage and apoE immunoreactivity in human apolipoprotein E, E4 isoform-specific, transgenic mice after global cerebral iscaemia / Horsburgh K. et al.. // Eur. J. Neurosci. 2000. - Vol. 12. - P. 4309-4317.

190. Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease contractile responsiveness to b-adrenergic agonists / Ungureanu-Longrois D. et al. // Circ. Res. 1995. - Vol. 77.-P. 494-502.

191. Influence of apolipoprotein E genotype on neuronal damage and ApoE immunoreactivity in human hippocampus following global ischemia / Horsburgh K. et al. // J. Neuropathol. Exp. Neurol. 1999. - Vol. 58. - P. 227-234.

192. Infusion of Human Umbilical Cord Blood Cells in a Rat Model of Stroke Dose-Dependently Rescues Behavioral Deficits and Reduces Infarct Volume / Vendrame Martina et al. // Stroke. 2004. - Vol. 35. - P. 2390-2395.

193. Inhibition of Factor IX(a) Is Protective in a Rat Model of Thromboembolic Stroke / Toomey John R. et al. // Stroke. 2002. - Vol. 33. - P. 578-585.

194. Intrathecal administration of a novel apoE-derived therapeutic peptide improves outcome following perinatal hypoxic-ischemic injury / McAdoo J.D. et al. // Neurosci. Lett. 2005. - Vol. 381. -P. 305-308.

195. Ischemic penumbra in a model of reversible middle cerebral artery occlusion in the rat / Memezawa H. et al. // Exp. Brain. Res. 1992. - Vol. 89. -P. 67-78.

196. Isoform-specific binding of apolipoprotein E to beta-amyloid / LaDu M.J. et al. I I J. Biol. Chem. 1994. - Vol. 269. - P. 23403-23406.

197. Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood- brain barrier transport of circulating Alzheimer's amyloid p / Martel C.L. et al. // J. Neurochem. 1997. - Vol. 69. - P. 19952004.

198. Isoform-specific effects of human apolipoprotein E on brain function revealed in apoE knockout mice: Increased susceptibility of females / Raber J. et al. // Proc. Natl. Acad. Sci. USA. 1998. - Vol. 95, № 18. - P. 10914-10919.

199. Kinesin superfamily motor protein KIF17 and mLin-10 in NMDA receptor-containing vesicle transport / M. Setou. et al. // Science. 2000. - Vol. 288. -P. 1796-1802.

200. Klapdor, K. Repeated acquisition of a spatial navigation task in mice: effects of spacing of trials and of unilateral middle cerebral artery occlusion / Klapdor K., Van Der Staay F. // Physiol. Behav. 1998. - Vol. 63. - P. 903-909.

201. Koehler, R.C. Large animal models of focal and global ischemia / Koehler R.C. // Cerebrovascular Disease: Pathophysiology,Diagnosis, and Management. Maiden, Mass: Blackwell Scientific Publications, 1998. P. 36-51.

202. Ladu, M. J. Lipoproteins in the Central Nervous System / Ladu Mary Jo. et al. // Annals of the New York Academy of Sciences. 2000. - Vol. 903. - P. 167-175.

203. LeBlanc, A.C. Regulation of apolipoprotein E gene expression after injury of the rat sciatic nerve / LeBlanc A.C., Poduslo J.F. // J. Neurosci. Res. 1990. -Vol. 25, №2.-P. 162-171.

204. Lee, V.M. Neurodegenerative tauopathies / V. M. Lee, M. Goedert, J. Q. Trojanowski // Annu. Rev. Neurosci. 2001. - Vol. 24. - P. 1121-1159.

205. Li, D.P. Intracarotid injection of endothelin-1 facilitates the activity of rostral ventrolateral medullary neurons via area postrema in rats / Li D.P., He R.R. // Sheng Li Xue Bao. 1999. - Vol. 51, № 3. - P. 263-71.

206. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity /Chang S. et al. // Proc. Natl. Acad. Sci. 2005. -Vol. 102. -P. 18694-18699.

207. Lipoprotein uptake by neuronal growth cones in vitro / Ignatius M.J. et al. // Science. 1987. - Vol. 236, №> 4804. - P. 959-962.

208. Long-lasting neuroprotective effect of postischemic hypothermia and treatment with an anti-inflammatory/antipyretic Evidence for chronic encephalopathic processes following ischemia / Coimbra, C. et al.-// Stroke. 1996. - Vol. 27. -P. 1578-1585

209. Long-term beneficial effects of BW619C89 on neurological deficit, cognitive deficit and brain damage after middle cerebral artery occlusion in the rat / Smith S.E. et al. //Neuroscience. 1997. - Vol. 77. - P. 1123-1135.

210. Long-term functionalend points following middle cerebral artery occlussion in the rat / Hudzik T. et al. //Pharm. Biochem. Beh. 2000. - Vol. 65. - P. 553562.

211. Louko, A-M. ApoE genotype and cognition after subarachnoid haemorrhage: a longitudinal study / Louko A-M., Vilkki J., Niskakangas T. // Acta Neurol. Scand.-2006.-Vol. 114.-P. 315-319.

212. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cellline / Holtzman D.M. et al. // Proc. Natl. Acad. Sci. USA. 1995. - Vol. 92, № 21.-P. 9480-9484.

213. Mahley, R.W. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology / Mahley R.W. // Science. 1988. -Vol. 240, № 4852. - P. 622-630.

214. Mahley, R.W. Apolipoprotein E: From atherosclerosis to Alzheimer's disease and beyond / Mahley R.W., Huang Y. // Curr. Opin. Lipidol. 1999. -Vol. 10, №3.-P. 207-217.

215. Mahley, R.W. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease / Mahley R.W., Weisgraber K.H., Huang Y. // Proc. Natl. Acad. Sci. USA. 2006. - Vol. 103, № 15. - P. 56445651.

216. Mahley, R.W. Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E / Mahley R.W., Ji Z-S.//J. Lipid. Res.-1999.-Vol. 40, № l.-P. 1-16.

217. McCarron, M. О. APOE genotype as a risk factor for ischemic cerebrovascular disease / McCarron M. O., Delong D., Alberts M. J. // Neurology. 1999. - Vol. 53.-P. 1308-1311.

218. Middle cerebral artery occlusion in the hypertensive and normotensive rat: a study of histopathology and behaviour / Grabowski M. et al. // J. Hyperten. -1988. -Vol. 6. -P. 405-411.

219. Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model / Belayev L. et al. // Stroke. 1996.-Vol. 27.-P. 1616-1622.

220. Miyata, M. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta amyloid peptides / Miyata M., Smith J.D. //Nat. Genet. 1996. - Vol. 14. - P. 55-61.

221. Modulation of mouse cardiac function in vivo by eNOS and ANP / Gyurko R. et al. // Am. J. Physiol. Heart Circ. Physiol. 2000. - Vol. 278. - P. H971-H981.

222. Moir, R.D. LRP-mediated clearance of Ap is inhibited by KPI-containing isoforms of APP / Moir R.D., Tanzi R.E. // Curr. Alzheimer. Res. 2005. - Vol. 2.-P. 269-273.

223. Moore, Z. W. Q. Apolipoprotein E inhibition of vascular hyperplasia and neointima formation requires inducible nitric oxide synthase / Moore Zachary W.Q., David Y. Hui // J. Lipid Res. 2005. -Vol. 46. -P. 2083-2090.

224. Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury / Chen Y. et al. // Neuroscience. 1997. - Vol. 80, № 4. - P. 12551262.

225. Mouse model of microembolic stroke and reperfusion / Atochin D.N. et al. // Stroke. 2004. - Vol. 35. - P. 2177-2182.

226. Mrak, R. E. Interleukin-1, neuroinflammation, and Alzheimer's disease / Mrak R.E., Griffin W. S. T. // Neurobiol. 2001. - Vol. 22. - P. 903-908.

227. Mukherjee, A. Lipid-dependent recruitment of neuronal Src to lipid rafts in the brain / A. Mukherjee, L. Arnaud, J. A. Cooper.// J. Biol. Chem. 2003. -Vol. 278.-P. 40806-40814.

228. Nascent astroctye particles differ from lipoproteins in CSF / LaDu, M.J. et al.. // J. Neurochem. 1998. - Vol. 70. - P. 2070-2081.

229. Neurodegeneration in the central nervous system of apoE-deficient mice / Masliah E. et al. // Exp. Neurol. 1995. - Vol. 136, № 2. - P. 107-122.

230. Neurological and behavioral outcomes of focal cerebral ischemia in rats / Wahl F.et al. // Stroke. 1992. - Vol. 23. - P. 267-272.

231. Neuronal position in the developing brain is regulated by mouse disabled- 1 / B. W. Howell, et al.,//Nature. 1997. - Vol. 389. - P. 733-737.

232. Neuronal specific regulatory elements in apolipoprotein E gene proximal promoter / Ramos M.C. et al. // NeuroReport. 2005. - Vol. 16, № 9. - P. 1027-1030.

233. Neurons of the human frontal cortex display apolipoprotein E immunoreactivity: implications for Alzheimer's disease / Metzger R.E. et al. // J. Neuropathol. Exp. Neurol. 1996. -Vol. 55. - P. 372-380.

234. Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes / Diedrich J.F. et al. // J. Virol. 1991. - Vol. 65. - P. 4759-4768.

235. Neuropathological endpoints in experimental stroke pharmacotherapy: the importance of both early and late evaluation / Valtyssow J. et al. // Acta Neurochir. 1994. - Vol. 129. - P. 58-63.

236. Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated / Tolar M. et al. // J. Neurosci. 1997. -Vol. 17. -P. 5678-5686.

237. Nicoll, J.A. Amyloid |3-protein, apoE genotype and head injury / Nicoll J.A., Roberts G.W., Graham D.I. //Ann. N.Y. Acad. Sci. 1996. - Vol. 777. - P. 271275.

238. Nitric oxide and peroxynitrite exert distinct effects on mitochondrial respiration which are differentially blocked by glutathione or glucose / Lizasoain I. et al. // Biochem. J. 1996. -Vol. 314. - P. 877- 880.

239. Nitric oxide inhibits the positive inotropic response to b-adrenergic stimulation in humans with left ventricular dysfunction / Hare J.M. et al. // Circulation. -1995. Vol. 92. - P. 2198 -2203.

240. Olton, D.S. Remembrance of places passed: Spatial memory in rats / Olton D.S., Samuelson R.J.// J. Exp. Psych.: An. Behav. Process. 1976. - Vol. 2 - P. 97-116.

241. Oxidative protein damage in cells engaged in beta.-amyloidosis is related to apoE genotype / Mazur-Kolecka B. [et al.] // NeuroReport. 2002. - Vol. 13. -P. 465-468.

242. Parkinson's Disease and Apolipoprotein E: Possible Association with Dementia but not Age at Onset / Parsian A. et al. // Genomics. 2002. - Vol. 79. - P. 458-461.

243. Pepe, M. G. Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In / Pepe M. G., Curtiss L. K. // J. Immunol. 1986. - Vol. 136. - P. 3716-3723.

244. Pepper, C.B. Nitric oxide: from laboratory to bedside / Pepper C.B., Shah A.M. // Spectrum. Int. 1996. - Vol.36, № 2. -P. 20-23.

245. Peroxisome proliferator-activated receptor- agonist reduces infarct size in transient but not in permanent ischemia / Shimazu Tomokazu et al. // Stroke. -2005.-Vol. 36.-P. 353-359.

246. Phenotypes of apolipoprotein В and apolipoprotein E after liver transplantation / M. Linton, et al. // J. Clin. Invest. 1991. - Vol. 81. - P. 270-281.

247. Predictors of cognitive decline after cardiac operation / Newman M.F. et al.. // Ann. Thorac. Surg. 1995. -Vol. 59. - P. 1326-1330.

248. Preliminary report of a genetic basis for cognitive decline after cardiac operations / Tardiff В. E. et al. // Ann. Thorac. Surg. 1997. - Vol. 64. - P. 715-720.

249. PROACT II: recombinant prourokinase (r-ProUK) in acute cerebral thromboembolism: initial trial results / Furlan A.J. et al. // Stroke. 1999. -Vol. 30.-P. 234.

250. Profile and regulation of apolipoprotein (apo) E expression in central nervous system in mice with targeting of green flourescent protein gene to the apoE locus / Xu Q. et al. // J. Neurosci. 2006. - Vol. 26, № 19. - P. 4985-4994.

251. Protective effect of apolipoprotein E against ischemic neuronal injury is mediated through antioxidant action / Kitagawa Kazuo. et al. // Journal of Neuroscience Research. 2002. - Vol. 68. - P. 226-232.

252. Protective effect of apolipoprotein E type 2 allele for late onset al.zheimer disease / Corder E.H. [et al.] // Nat. Genet. 1994. -Vol. 7, № 2. - P. 180-184.

253. Protective effect of apolipoprotein E-mimetic peptides on N-methyl-Daspartate excitotoxicity in primary rat neuronal-glial cell cultures / Aono M. et al. // Neuroscience. 2003. - Vol. 116. - P. 437-45.

254. Purification of apolipoprotein E attenuates isoform-specific binding to □amyloid / LaDu M.J. et al. // J. Biol. Chem. 1995. - Vol. 270, № 16. - P. 9039-9042.

255. Quantitative measurement of motor and somatosensory impairments after mild (30 min) and severe (2 h) transient middle cerebral artery occlusion in rats / Zhang L. et al. //J. Neuro. Sci. 2000. - Vol. 174. - P. 141-146.

256. Rabbit very low density lipoprotein receptor: A low density lipoprotein receptor-like protein with distinct ligand specifity / Takahashi S. et al. // Proc. Natl. Acad. Sci. USA. 1992. - Vol. 89. - P. 9252-9256.

257. Rail, S.C. Jr. Human apolipoprotein E. The complete amino acid sequence / Rail S.C. Jr., Weisgraber K.H., Mahley R.W. // J. Biol. Chem. 1982. - Vol. 257, №8.-P. 4171-4178.

258. Rail, S.C. Jr. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects / Rail S.C. Jr. // Proc. Natl. Acad. Sci. USA. 1982. - Vol. 79, № 15. - P. 4696-4700.

259. Recommendations for standards regarding preclinical neuroprotective and restorative drug development stroke therapy academic industry roundtable (STAIR) // Stroke. 1999. - Vol. 30. - P. 2752-2758.

260. Reddick, R.L. Atherosclerosis in mice lacking ApoE: evaluation of lesional development and progression / Reddick R.L., Zhang S.H., Maeda N. // Arterioscler. Thromb. 1994. - Vol. 14. - P 141-147,

261. Regionally specific neuronal expression of human apoE gene in transgenic mice / Xu P.T. et al. // Neurosci. Lett. 1998. - Vol. 246, № 2. - P. 65-68.

262. Reidy, M. A. Factors controlling smooth muscle cell proliferation / Reidy M. A. // Arch. Pathol. Lab. Med. 1992. - Vol. 116. -P. 1276-1280.

263. Remnant lipoprotein particles are taken up into myocardium throuth VLDL receptor. A possible mechanism for cardiac fatty acid metabolism / Kamataki A. et al.. // Biochem. Biophys. Res. Commun. 2002. - Vol. 293. - P. 1007-1013.

264. Reynolds, I. J. Mitochondrial stop and go: signals that regulate organelle movement / Reynolds I. J., Rintoul G. L. // Sci. STKE. 2004. - Vol. 251. - P. 46.

265. Robinson R. Differential behavioral and biochemical effects of rightand left hemispheric cerebral infarction in the rat / Robinson R. // Science. 1979. -Vol. 205.-P. 707-710.

266. Roselaar, S. E. Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo / Roselaar S. E., Daugherty A. // J. Lipid Res. 1998. - Vol. 39. - P. 740-743.

267. Roses, A.D. Apolipoprotein E, a gene with complex biological interactions in the aging brain / Roses A.D. // Neurobiol. Dis. 1997. - Vol. 4, № 3-4. - P. 170-185.

268. Schwartz, S. M. Smooth muscle migration in atherosclerosis and restenosis / Schwartz, S. M. // J. Clin. Invest. 1997. - Vol. 11 (Suppl.). - P. 87-89.

269. Sensorimotor and cognitive consequences of middle cerebral artery occlusion in rats / Markgraf C. et al. // Brain. Res. 1992. - Vol. 575. - P. 238-246.

270. Serot, J.-M. Choroid plexus, aging of the brain, and Alzheimer's disease / Serot J-M., Bene' M-C., Faure G.C. // Front. Biosci. 2003. -Vol. 8. - P. 515521.

271. Shinoda, M. Pharmacological studies of a novel prolyl endopeptidase inhibitor, JTP-4819, in rats with middle cerebral artery occlusion / Shinoda M., Matsuo A., Toide K. // Eur. J. Pharm. 1996. - Vol. 305. - P. 31-38.

272. Sialylated human apolipoprotein E (apoEs) is preferentially associated with neuron-enriched cultures from APOE transgenic mice / Xu P-T. et al. // Neurobiol. Dis. 1999. - Vol. 6. - P. 63-75.

273. Skene, J.H. Denervated sheath cells secrete a new protein after nerve injury / Skene J.H., Shooter .EM. // Proc. Natl. Acad. Sci. USA. 1983. - Vol. 80, № 13.-P. 4169-4173.

274. Spatial cognitive performance after chronic focal cerebral ischemia in rats / Yonemori F.et al. // J. Cereb. Blood Flow. Metab. 1999. - Vol. 19. - P. 483494.

275. Specific regional transcription of apolipoprotein E in human brain neurons / Xu P-T. et al. // Am. J. Pathol. 1999. - Vol. 154. - P. 601- 611.

276. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth / Bellosta S. et al. // J. Biol. Chem. -1995. Vol. 270. - P. 27063-27071.

277. Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin / Nussler A.K. et al.. // J.Exp.Med. 1992. - Vol. 176. -P. 261-264.

278. Striatal dopamine-mediated motor behavior is altered following occlusion of the middle cerebral artery/ Borlongan C.V. et al.. // Pharm. Biochem. Beh. -1995.-Vol. 52.-P. 225-229.

279. Stroemer, R.P. Enhanced neocortical neural sprouting, synaptogenesis, and behavioral recovery with Damphetamine therapy after neocortical infarction in rats / Stroemer R.P., Kent T.A., Hulsebosch C.E. // Stroke. 1998. - Vol. 29. -P. 2193-2381.

280. Structure, chromosome location, and expression of the human very low density lipoprotein receptor gene / Sakai J. et al.. // J. Biol. Chem. 1994. - Vol. 269. -P. 2173-2182.

281. Swertfeger, D. K. Apolipoprotein E receptor binding versus heparan sulfate proteoglycan binding in its regulation of smooth muscle cell migration and proliferation / Swertfeger D. K., Hui D. Y.// J. Biol. Chem. 2001. - Vol. 276. -P. 25043-25048.

282. Swertfeger, D. K. Low density lipoprotein receptor-related protein mediates apolipoprotein E inhibition of smooth muscle cell migration / D. Swertfeger, K., G. Bu, D. Y. Hui // J. Biol. Chem. 2002. - Vol. 277. -P. 4141-4146.

283. Synergistic effects of citicoline and MK-801 in temporary experimental focal ischemia / Onal M.Z. et al. // Stroke. 1997. - Vol. 28. - P. 1060-1065.

284. Synthesis and regulation of apolipoprotein E during the differentiation of human neuronal precursor NT2/D1 cells into postmitotic neurons / Ferreira S. et al. // Exp. Neurol. 2000. - Vol. 166. - P. 415- 421.

285. Synthesis of apolipoprotein E (apoE) mRNA by human neuronal-type SK N SH-SY 5Y cells and its regulation by nerve growth factor and apoE / Soulie C. et al. // Neurosci. Lett. 1999. -Vol. 265, № 2. - P. 147-150.

286. Takizawa, S. Animal models of cerebral ischemia. Rat models / Takizawa S., Hakim A.M. // Cerebrovasc. Dis. 1991. - Vol. 1. - P. 16-21.

287. Taylor, J. P. Toxic proteins in neurodegenerative disease / Taylor J. P., Hardy J., Fischbeck К. H. / Science. 2002. - Vol. 296. - P. 1991-1995.

288. Teasdale, G. M. The association between APOE 4, age and outcome after head injury: a prospective cohort study / Teasdale G. M. et al. // Lancet. 1997. -Vol. 350.-P. 1069-1071.

289. The apoE-epsilon 4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics / Tang M.X. et al. // J. Am. Med. Assoc. -1998.-Vol. 279, № 10. -P. 751-755.

290. The apolipoprotein multigene family: biosynthesis, structure, structure-function relationships, and evolution / Li, W-H. et al.. // J. Lipid Res. 1988. -Vol. 29. P. 245-271.

291. The influence of fpolipoprotein E genotipe on outcome after spontaneous subarachnoid hemorrhage: a preliminary study / Dunn L.T. et al.. // Neurosurgery. 2001. - Vol. 48. - P. 1006-1010.

292. The low density lipoprotein receptor-related protein (LRP), a multifunctional apoE receptor, modulates hippocampal neurite development / Narita M. et al.. // J. Neurochem. 1997. - Vol. 68. - P. 587-595.

293. The national institute of neurological disorders, and stroke rt-PA study group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. -1995. - Vol. 333. - P. 1581-1587.

294. The very low density lipoprotein (VLDL) receptor a peripheral lipoprotein receptor for remnant lipoproteins into fatty acid active tissues / Takahashi Sadao et al. // Molecular and Cellular Biochemistry. - 2003. - Vol. 248, № 1-2. - P. 121-127.

295. The very low-density lipoprotein receptor: Characterisation and functions as a peripheral lipoprotein receptor / Takahashi Sadao et al. // J. of Atherosclerosis and Thrombosis. 2004. - Vol. 11, № 4. - P. 200-209.

296. The World Health Report , 1999. World Health Organisation (WHO). -Geneva. 1999.- 119 p.

297. Tolias, C.M. Critical appraisal of neuroprotection trials in head injury: what have we learned? / Tolias C.M., Bullock M.R. // Neuro.Rx. 2004. - Vol. 1. - P. 71-79.

298. Transient focal cerebral ischemia induces sensorimotor deficits in mice / Gerlai R. et al. // Behav. Brain. Res. 2000. - Vol. 108. - P. 63-71.

299. Truncated apolipoprotein E (apoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity. T / Tolar M. et al. // J. Neurosci. 1999. -Vol. 19.-P. 7100-7110.

300. Utermann, G. Genetic control of human apolipoprotein E polymorphism: Comparison of one- and twodimensional techniques of isoprotein analysis / Utermann G., Steinmetz A., Weber W. // Hum. Genet. 1982. - Vol. 60, № 4. -P. 344-351.

301. Vascular apolipoprotein E expression and recruitment from circulation to modulate smooth muscle cell response to endothelial denudation / Z. W. Q. Moore et al. // Am. J. Pathol. 2004. - Vol. 164. -P. 2109-2116.

302. Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit / R. L. Wilensky et al. // Circulation. -1995. Vol. 92. - P. 2995-3005.

303. Vincent, B. Astrocytes down-regulate neuronal f3-amyloid precursor protein expression and modify its processing in an apolipoprotein E isoform-specific manner / Vincent В., Smith J.D. // Eur. J. Neurosci. 2001. - Vol. 14, № 2. - P. 256-266.

304. Weisgraber, K.H. Apolipoprotein E: structure-function relationships / Weisgraber K.H. // AdVol. Protein. Chem. 1994. - Vol. 45. - P. 249-302.

305. Weisgraber, K.H. Human apolipoprotein E: The Alzheimer's disease connection / Weisgraber K.H., Mahley R.W. // FASEB J. 1996. - Vol. 10, № 13.-P. 1485-1494.

306. Weisgraber, K.H. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms / Weisgraber K.H., Rail S.C. Jr., Mahley R.W. // J. Biol. Chem. 1981. - Vol. 256, № 17. -P. 9077-9083.

307. Wisniewski, T. A pathological chaperone protein in patients with cerebral and systemic amyloid / Wisniewski Т., Frangione B. // Neurosci. Lett. 1992. - Vol. 135, №2.-P. 235-238.

308. Yonemori, F. Spatial memory disturbance after focal cerebral ischemia in rats / Yonemori F., Yamada H., Yamaguchi T. et al. // J. Cereb. Blood. Flow Metab. 1996.-Vol. 16.-P. 973-980.

309. Zannis, V.I. Human apolipoprotein E isoprotein subclasses are genetically determined / Zannis V.I., Just P.W., Breslow J.L. // Am. J. Hum. Genet. 1981. -Vol. 33, №1.-P. 11-24.

310. Zannis, V.I. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslationalmodification / Zannis V.I., Breslow J.L. // Biochemistry. 1981. - Vol. 20, № 4. -P. 1033-1041.

311. Zhang, Y. The effect of intraischemic mild hypothermia on focal cerebral ischemia/reperfusion injury / Zhang Yonghua, K.C. Wong, Zhijie Zhang // Acta Anaesthesiol. Sin. 2001. - Vol. 39. - P. 65-69.

312. Zivin, J.A. Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke / Zivin J.A., Massarella V. // Arch. Neurol. 1991. -Vol. 48.-P. 1235-1235.